Table 5.
Mean (± SD) percentage change from baseline for mean activity counts for each week of the study, for each group and the combined treatment group. Baseline activity was defined as the mean activity count per minute over the first 2 weeks of the study for each cat, before treatment
| Weeks of study | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| Weeks after treatment | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| Placebo | −1.7 (15.3) | −4.0 (14.3) | −5.0 (14.2) | −5.3 (9.7) | −4.9 (9.6) | −6.1 (20.9) | −5.2 (24.3) | −5.6 (22.5) | 8.9 (25.3) |
| T1 (NV‐02 0.4 mg/kg) | 11.5 (21.1) | 15.4 (24.7) | 14.9 (18.1) | 15.3 (22.1) | 5.1 (26.9) | 7.8 (18.4) | −0.6 (17.4) | 4.5 (19.2) | 2.8 (20.2) |
| T2 (NV‐02 0.8 mg/kg) | 3.1 (11.1) | 7.5 (14.4) | 5.8 (13.0) | 8.2 (21.6) | 11.4 (13.2) | 8.6 (16.0) | 5.4 (13.6) | −2.2 (16.7) | 3.1 (20.4) |
| T1 and T2 combined | 6.9 (16.5) | 11.1 (19.7) | 9.9 (15.9) | 11.4 (21.6) | 8.5 (20.3) | 8.2 (16.7) | 2.7 (15.3) | 0.8 (17.8) | −3.0 (19.8) |
SD, standard deviation; “Weeks after treatment,” the number of weeks following the administration of NV‐02 or placebo.